甲状腺癌RET基因检测与临床应用专家共识(2021版)

Expert consensus on rearranged during transfection gene testing and clinical application in thyroid cancer(Version 2021)

RET(rearranged during transfection)基因变异被认为是甲状腺癌、非小细胞肺癌和其他多种癌症形成发展的重要因素。10%~20%的甲状腺乳头状癌(papillary thyroid carcinoma,PTC)存在RET基因重排/融合;体细胞(60%~90%)或胚系(100%)RET基因突变见于甲状腺髓样癌(medullary thyroid carcinoma,MTC)[1]。一般认为,RET基因是RET驱动型恶性肿瘤的治疗靶点,靶向治疗是晚期伴有RET基因重排/融合的分化型甲状腺癌(differentiated thyroid carcinoma,DTC)和RET基因点突变的晚期MTC的重要治疗方法。